Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 5/20 | 0.33 |
| ▸ | DRD2 | P14416 | 5/20 | 0.33 |
| ▸ | HTR2A | P28223 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518788 | 0.92 | ADORA2A (0.36) | ADORA2APDE10AP2RX7ALOX15HTR1A | |
| SCHEMBL518934 | 0.89 | PDE10A (0.40) | ADORA2APDE10AP2RX7ALOX15HTR1A | |
| SCHEMBL518462 | 0.89 | ADORA2A (0.39) | ADORA2APDE10AP2RX7ALOX15HTR1A | |
| SCHEMBL519104 | 0.88 | ADORA2A (0.40) | ADORA2APDE10AP2RX7ALOX15HTR1A | |
| SCHEMBL17677293 | 0.86 | ADORA2A (0.43) | ADORA2APDE10AP2RX7ALOX15HTR1A | |
| SCHEMBL518759 | 0.86 | ADORA2A (0.35) | ADORA2APDE10AP2RX7ALOX15HTR1A | |
| SCHEMBL518758 | 0.86 | ADORA2A (0.35) | ADORA2APDE10AP2RX7ALOX15HTR1A | |
| SCHEMBL8370043 | 0.82 | P2RX7 (0.41) | ADORA2APDE10AP2RX7ALOX15HTR1A | |
| SCHEMBL10258608 | 0.82 | ALOX15 (0.36) | ADORA2AP2RX7ALOX15HTR1ADRD2 | |
| SCHEMBL10291032 | 0.80 | PDE10A (0.38) | ADORA2APDE10AP2RX7HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916566-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8916566-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197651-A1 | Pyridazinone compounds | PDE3A, PDE5A, PDE3B | ADORA2A 425/4885PDE10A 9/4885P2RX7 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.